Compare Novo Nordisk A/S (NVO) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Raymond James Financial, Inc. — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Raymond James Financial, Inc. trades at $168.25 (market cap $32.80B). The key difference: Novo Nordisk A/S is far larger — about 6.7× Raymond James Financial, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | RJF | |
|---|---|---|
Market Cap | $220.53B | $32.80B |
Sector | Health | Financials |
52-Week High | $71.70 | $176.43 |
52-Week Low | $35.29 | $140.89 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | 1.28% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
